FREE SUBSCRIPTION

Receive the WSMS Newsletter
and
Updates from NAMC Free!

Free Registration
:

 
  Name:
 
  E-mail Address:
 

**Privacy Policy: Emails are not shared with third parties, they are only used for NAMC related material ONLY**

To Unsubscribe Click Here


Call in Your Stock Questions


Press Releases


Company Profiles

 

Click to Register for Free

 

Get a Stock Quote


CNN Money
Market Watch
SEC
NASD
OTCBB
Free Edgar
Pink Sheets
NYSE
AMEX
NASDAQ
IPO's
REG FD
Economic Calendar
Streetiq.com

 

 

Company Profiles
Custom RSS News Feed
Custom Podcast Feed
Audio Releases
Video Releases
Support from NAMC
PR Assistance
Multimedia Room
Click to Register

 

 

Google News
MSN News
Ask Jeeves News
Lycos News
News Now
Feedster

and more..

 

 

 

 

 

The NAMC Newswire Features

"WALL STREET TO MAIN STREET"

The Daily Financial Newsletter that Features Stocks that You Should Know About

The Investors Corner: Cholesterol Drug Failure Weighs on Pfizer Inc (NYSE: PFE) but Creates Opportunity for Investors

With Louis Victor, Host of The Syndicated Radio Show "Wall Street to Main Street"

Now Featured on Streetiq.com

FREE SUBSCRIPTION

Receive the WSMS Newsletter
and
Updates from NAMC Free!

Free Registration
:

 
  Name:
 
  E-mail Address:
 

**Privacy Policy: Emails are not shared with third parties, they are only used for NAMC related material ONLY**

To Unsubscribe Click Here

 

In what most analyst see as a blow to Pfizer Inc (NYSE: PFE) may just become an opportunity for investors looking for cheap Pfizer stock.

Over the weekend the world’s largest drugmaker announced that they would halt the development of torcetrapib, a "good-cholesterol" booster that was seen as Pfizer's replacement for its blockbuster Lipitor drug, which loses patent protection in 2010.

 

A recommendation to halt the study for torcetrapib from an independet board that Pfizer set up due was handed down to an unexpected number of deaths, According to Pfizer 82 patients that were taking a combination of torcetrapib and Lipitor died and that is compared with 51 deaths in the study where patients were only prescribed Lipitor. There were a total of 15,000 patients particpating in the study, 7,500 each..

 


Now this news prompted downgrades at JP Morgan (NYSE: JPM), Lehman Brothers (NYSE: LEH) and Merrill Lynch (NYSE: MER).

 

The news and domino effect of the downgrades has put pressure on the stock overseas and this is sure to follow through once the U.S. markets open up this morning.

 

Some analyst believe that this recent situation may lead to Pfizer’s revenue growth to slow down dramatically until 2009.

 

Investors need to keep in mind that we are at the tail end of 2006 and this news may have prompted one instituion to step aside but that along with analyst downgrades may force other institutions to follow suit, but it is likely that they will reenter Pfizer in early 2007. So this may just be an opportunity for investors to position themselves in the pharmaceutical giant close to their 52-week lows.

 

Pfizer closed at $27.86 on Friday and is likely to open anywhere from $3 to $5 lower this morning.
 
 
Louis Victor
NAMC Newswire

 
 
NAMC Newswire Note
 
Go to the NAMC Newswire for updates at namcnewswire.com and you can listen to the NAMC Radio for the audio version of “Wall Street to Main Street” at namcnewswire.com/namcradio
 
To register to receive the Wall Street to Main Street Free Daily Newsletter Click Here or go to our site and click on the Newsletter section. namcnewswire.com/newsletter
CEO’s that want to contact us can do so by going to namcnewswire.com  or call us at .
 
 
Disclaimer:
None of the information contained on the NAMC Newswire constitutes a recommendation by the NAMC Newswire, its journalist, nor its parent company that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific investors or person. Each individual investor must make their own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy featured on the NAMC Newswire or NAMC Radio Any past results are not necessarily indicative of future performance. The NAMC Newswire, its journalist nor its parent company does not guarantee any specific outcome or profit, and all investors should be aware of the real risk of loss in following any strategy or investments featured on the NAMC Newswire or the NAMC Radio. The strategy or investments discussed may fluctuate in price or value and investors may get back less than you invested. Before acting on any information featured on the NAMC Newswire website or the NAMC Radio segment, investors should consider whether it is suitable for their particular circumstances and strongly consider seeking advice from their own financial or investment adviser. Investors are also urged to do their own due diligence before investing in any security.
 
All opinions featured on the NAMC Newswire or NAMC Radio are based upon information that is considered to be reliable, but neither the NAMC Newswire, its journalist, its parent company, affiliates nor assigns warrant its completeness or accuracy, and it should not be relied upon as such. The statements and opinions featured on the NAMC Newswire by its journalist are based on their outlook at the time of the statement or opinion, and are subject to change without notice. NAMC may at times hold a position in the companies that it features, in these cases appropriate disclosure is made.

 

 
  
© NAMC Newswire